Global Overactive Bladder (OAB) Therapeutics Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Overactive Bladder (OAB) Therapeutics Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Overactive bladder (OAB) is a bladder disorder that results in an abnormal urge to urinate, urinary frequency, and nocturia (voiding at night). Some patients may also experience urinary incontinence (involuntary loss of bladder control). This report only focuses on the treatment drugs and Device.
Overactive Bladder (OAB) Therapeutics report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Overactive Bladder (OAB) Therapeutics market is projected to reach US$ 6042.2 million in 2034, increasing from US$ 5100 million in 2022, with the CAGR of 2.4% during the period of 2024 to 2034. Demand from Hosptial and Clinci are the major drivers for the industry.
Global Overactive Bladder Treatment key players include Allergan, Astellas Pharma, Pfizer, Johnson & Johnson, Medtronic, etc. Global top five manufacturers hold a share about 90%. United States is the largest market, with a share about 60%, followed by Europe, with a share about 15 percent. In terms of product, Drugs is the largest segment, with a share about 95%. And in terms of application, the largest application is Idiopathic Overactive Bladder, followed by Neurogenic Overactive Bladder.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Overactive Bladder (OAB) Therapeutics market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Allergan
Astellas Pharma
Hisamitsu Pharmaceutical
Pfizer
Ferring
GlaxoSmithKline
Ion Channel Innovations
Kwang Dong Pharmaceutical
Lanzhou Institute of Biological Products
Merck
ONO Pharmaceutical
Sanofi
Tengion
Teva Pharmaceutical Industries
Segment by Type
Anticholinergic Agents
Beta-3 Adrenoreceptor Agonists
Hosptial
Clinci
Other
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Overactive Bladder (OAB) Therapeutics market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Overactive Bladder (OAB) Therapeutics, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Overactive Bladder (OAB) Therapeutics industry.
Chapter 3Historical (2024-2022) and forecast (2024-2034) volume and revenue analysis of Overactive Bladder (OAB) Therapeutics in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Overactive Bladder (OAB) Therapeutics introduction, etc. Overactive Bladder (OAB) Therapeutics Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Overactive Bladder (OAB) Therapeutics market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Overactive Bladder (OAB) Therapeutics report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Overactive Bladder (OAB) Therapeutics market is projected to reach US$ 6042.2 million in 2034, increasing from US$ 5100 million in 2022, with the CAGR of 2.4% during the period of 2024 to 2034. Demand from Hosptial and Clinci are the major drivers for the industry.
Global Overactive Bladder Treatment key players include Allergan, Astellas Pharma, Pfizer, Johnson & Johnson, Medtronic, etc. Global top five manufacturers hold a share about 90%. United States is the largest market, with a share about 60%, followed by Europe, with a share about 15 percent. In terms of product, Drugs is the largest segment, with a share about 95%. And in terms of application, the largest application is Idiopathic Overactive Bladder, followed by Neurogenic Overactive Bladder.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Overactive Bladder (OAB) Therapeutics market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Allergan
Astellas Pharma
Hisamitsu Pharmaceutical
Pfizer
Ferring
GlaxoSmithKline
Ion Channel Innovations
Kwang Dong Pharmaceutical
Lanzhou Institute of Biological Products
Merck
ONO Pharmaceutical
Sanofi
Tengion
Teva Pharmaceutical Industries
Segment by Type
Anticholinergic Agents
Beta-3 Adrenoreceptor Agonists
Segment by Application
Hosptial
Clinci
Other
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Overactive Bladder (OAB) Therapeutics market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Overactive Bladder (OAB) Therapeutics, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Overactive Bladder (OAB) Therapeutics industry.
Chapter 3Historical (2024-2022) and forecast (2024-2034) volume and revenue analysis of Overactive Bladder (OAB) Therapeutics in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Overactive Bladder (OAB) Therapeutics introduction, etc. Overactive Bladder (OAB) Therapeutics Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Overactive Bladder (OAB) Therapeutics market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices